Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024

Description

Insomnia Therapeutics Market Growth & Trends:

The global insomnia therapeutics market is expected to reach USD 3.74 billion by 2030, expanding at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level, and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia & awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings & awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic nonbenzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai's Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Insomnia Therapeutics Market Report Highlights:

Benzodiazepines dominated the market and accounted for a market share of 28.9% in 2023. Benzodiazepines are useful for insomnia associated with acute stress.
Over-the-counter accounted for the largest market revenue share of 61.4% in 2023, owing to the increasing number of patients with insomnia.
The North America insomnia therapeutics market dominated the market in 2023 with a market share of 35.4%.

Product Code: GVR-2-68038-213-6

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Insomnia Therapeutics Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Insomnia Therapeutics Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Insomnia Therapeutics Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Insomnia Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Benzodiazepines
- 4.3.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Nonbenzodiazepines
- 4.4.1. Nonbenzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Antidepressants
- 4.5.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Orexin Antagonists
- 4.6.1. Orexin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Melatonin Antagonists
- 4.7.1. Melatonin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insomnia Therapeutics Market: Sales Channel Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Insomnia Therapeutics Market: Sales Channel Movement Analysis, 2023 & 2030 (USD Million)
5.3. Prescription
- 5.3.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Over-the Counter
- 5.4.1. Over-the Counter Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insomnia Therapeutics Market: Regional Estimates & Trend Analysis

6.1. Insomnia Therapeutics Share, By Region, 2023 & 2030 (USD Million)
6.2. North America
- 6.2.1. North America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. U.S.
  - 6.2.2.1. U.S. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Canada
  - 6.2.3.1. Canada Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.4. Mexico
  - 6.2.4.1. Mexico Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
- 6.3.1. Europe Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. U.K.
  - 6.3.2.1. U.K. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Germany
  - 6.3.3.1. Germany Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. France
  - 6.3.4.1. France Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.5. Italy
  - 6.3.5.1. Italy Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.6. Spain
  - 6.3.6.1. Spain Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.7. Denmark
  - 6.3.7.1. Denmark Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.8. Sweden
  - 6.3.8.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.9. Norway
  - 6.3.9.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
- 6.4.1. Asia Pacific Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. Japan
  - 6.4.2.1. Japan Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. China
  - 6.4.3.1. China Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. India
  - 6.4.4.1. India Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. South Korea
  - 6.4.5.1. South Korea Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Thailand
  - 6.4.6.1. Thailand Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
- 6.5.1. Latin America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Brazil
  - 6.5.2.1. Brazil Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Argentina
  - 6.5.3.1. Argentina Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
- 6.6.1. Middle East and Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. South Africa
  - 6.6.2.1. South Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Saudi Arabia
  - 6.6.3.1. Saudi Arabia Insomnia Therapeutics and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. UAE
  - 6.6.4.1. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.5. Kuwait
  - 6.6.5.1. Kuwait Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
- 7.4.1. Takeda Pharmaceutical Company Ltd.
  - 7.4.1.1. Participant's Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Vanda Pharmaceuticals
  - 7.4.2.1. Participant's Overview
  - 7.4.2.2. Financial Performance
  - 7.4.2.3. Product Benchmarking
  - 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Merck & Co., Inc.
  - 7.4.3.1. Participant's Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. Pfizer Inc.
  - 7.4.4.1. Participant's Overview
  - 7.4.4.2. Financial Performance
  - 7.4.4.3. Product Benchmarking
  - 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. Teva Pharmaceutical Industries Ltd.
  - 7.4.5.1. Participant's Overview
  - 7.4.5.2. Financial Performance
  - 7.4.5.3. Product Benchmarking
  - 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Mylan N.V.
  - 7.4.6.1. Participant's Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Sumitomo Dainippon Pharma Co., Ltd
  - 7.4.7.1. Participant's Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. Sanofi
  - 7.4.8.1. Participant's Overview
  - 7.4.8.2. Financial Performance
  - 7.4.8.3. Product Benchmarking
  - 7.4.8.4. Recent Developments/ Strategic Initiatives
- 7.4.9. Paratek Pharmaceuticals Inc.
  - 7.4.9.1. Participant's Overview
  - 7.4.9.2. Financial Performance
  - 7.4.9.3. Product Benchmarking
  - 7.4.9.4. Recent Developments/ Strategic Initiatives
- 7.4.10. Ebb Therapeutics
  - 7.4.10.1. Participant's Overview
  - 7.4.10.2. Financial Performance
  - 7.4.10.3. Product Benchmarking
  - 7.4.10.4. Recent Developments/ Strategic Initiatives

Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030